A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(6 sites) China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, He'nan Hebei General Hospital, Shijiazhuang, Hebei The First Affiliated Hospital,College of Medicine,Zhejiang University, Hangzhou, Zhejiang Peking university first hospital, Beijing Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai
Key details Sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborators
Shanghai Pharmaceuticals Holding Co., Ltd
Enrollment target
~52 participants
Primary completion
December 2026
Age range
18 Years – 75 Years
Last updated February 2025